The panel considers grant applications that deal with detection and diagnostics of bacteria, non-HIV viruses, eukaryotic pathogens, parasites, and prions.

 

The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Topics


  • Technological and/or conceptual innovations for the detection or quantitation of bacteria, non-HIV viruses, eukaryotic pathogens, and prions.
  • Novel platforms (molecular or immunological assays/devices) for simultaneous detection of pathogens and, antimicrobial drug susceptibility and resistance
  • Point-of-care, point-of-need, and point-of-use microbial detection and quantitation systems for Physician’s office and resource-challenged settings
  • Development of novel agents or methods to detect and quantitate pathogens embedded within biofilms in vivo and on medical devices
  • Detection and quantitation of pathogens and toxins of microbial origin in food or drinking water
  • Advances in sterilization, decontamination or disinfection technologies
  • Development of novel applications for microbial bioremediation

Overlaps with Closely Related Study Sections

There are shared interests with Small Business: Non-HIV Anti-Infective Therapeutics Special Emphasis Panel (IDM (10)) in the area of microbiology of infectious agents. Grant applications that seek to develop antibiotic agents that include effectiveness in the context of biofilms may be reviewed in IDM (10). Applications addressing the development of agents or methods to detect or combat biofilms in vivo and on medical devices may be reviewed in IDM (12).

There are shared interests with Small Business: Biological Chemistry, Biophysics, and Assay Development (IMST (10)) in the area of microbiology of infectious agents. Grant applications that address technological advances for biophysical measurements, high-throughput methods, or molecular screens as related to microbial diagnostics or quantification may be reviewed in IMST (10). Applications that focus on the microbial pathogen in the context of diagnostics or quantification may be reviewed in IDM (10).

There are shared interests with Small Business: Instrumentation, Environmental, and Occupational Safety (IMST (12)) in the area of microbiology of infectious agents. Grant applications that address chemical, optical, electronic, spectroscopic or microscopic technologies that are applied to microbial environmental monitoring or portable point-of-care devices may be reviewed in IMST (12). Applications that focus on the microbial pathogen in the context of environmental monitoring or point-of-care devices may be reviewed in IDM (10).

There are shared interests with Small Business: Computational, Modeling, and Biodata Management (IMST (14)) in the area of microbiology of infectious agents. Applications that advance bioinformatics, computational and modeling technologies as related to microbial detection and quantification may be reviewed in IMST (14). Applications that focus on the microbial pathogen in the context of using existing technologies may be reviewed in IDM (10).

There are shared interests with Small Business: Innovative Immunology Research (IMM (10)) in the area of microbiology of infectious agents. Grant applications that seek to develop diagnostic immunoassays and immunological markers for the detection of microbial pathogens may be reviewed in IMM (10). Applications that focus on the microbial pathogen while using immunological methods may be reviewed in IDM (12).

There are shared interests with Clinical Research and Field Studies of Infectious Diseases (CRFS) in the area of infectious disease diagnostic development. R01 grant applications addressing diagnostic development or any applications addressing diagnostics for the purpose of advancing epidemiological principles or questions related to infectious disease transmission may be reviewed in CRFS. R21 and R03 applications that seek to develop new technologies for diagnostic purposes may be reviewed in IDM (12).